BullFrog AI Strengthens Capabilities of its AI Platform through Expansion of Licensing Agreement with Johns Hopkins Applied Physics Laboratory
“We are committed to firmly establishing BullFrog AI as the undisputed leader in artificial intelligence-driven drug development,” said Vin Singh, Founder and CEO of BullFrog AI.
- “We are committed to firmly establishing BullFrog AI as the undisputed leader in artificial intelligence-driven drug development,” said Vin Singh, Founder and CEO of BullFrog AI.
- "Our expanded license with APL is a testament to our relentless pursuit of innovation, enabling us to harness the full potential of AI in accelerating the development of life-saving therapies.
- This breakthrough technology not only has the potential to disrupt the industry, but also transform countless lives across the globe."
- The latest APL license improvements enable bfLEAP™ capabilities to be much more robust, both from a software perspective and mathematically.